Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 11 → 12·22:28, 1 Dec 2024
Difference between revision 11 and revision 12 of Glucose-dependent insulinotropic polypeptide. 6 lines changed; the page grew by 118 bytes.
| Revision 11 — 08:15, 10 Nov 2024 AmylinAmos (talk) add the reference range with the assay it was established on 5,459 bytes +159 | Revision 12 — 22:28, 1 Dec 2024 BacWaterBarnaby (talk) rm the sentence implying the hormone is a drug 5,577 bytes +118 | ||
|---|---|---|---|
| 42 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide oral in type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 42 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide oral in type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| 43 | 43 | ||
| + | 44 | == See also == | |
| + | 45 | * [[Glucagon-like peptide-1]] | |
| + | 46 | * [[GLP-1 receptor]] | |
| + | 47 | * [[Incretin effect]] | |
| + | 48 | * [[Dipeptidyl peptidase-4]] | |
| + | 49 | ||
| 44 | {{DEFAULTSORT:Glucose-dependent insulinotropic polypeptide}} | 50 | {{DEFAULTSORT:Glucose-dependent insulinotropic polypeptide}} |
| 45 | [[Category:Incretin biology]] | 51 | [[Category:Incretin biology]] |